Introduction {#Sec1}
============

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma in adults, presenting an annual incidence estimated in 3--5 cases per 100,000 inhabitants \[[@CR1], [@CR2]\]. The gold standard treatment for DLBCL includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) administered every 14 or 21 days, achieving long-term disease-free survival in approximately 60 % of patients \[[@CR3]--[@CR6]\]. The dissemination in the central nervous system (CNS) is an uncommon complication with an incidence rate of about 5 %, but can rise up to 25 % depending on patient's risk factors, such as elevated serum lactate dehydrogenase (LDH) or the implication of extranodal sites or testes \[[@CR7]--[@CR14]\]. CNS involvement occurs early in the course of the DLBCL (4.7--9.0 months from diagnosis) and is associated with poor outcomes since survival drops to 2--5 months. Prophylaxis has been demonstrated to reduce CNS relapse and improve survival rates \[[@CR15], [@CR16]\]. For this reason, American and European guidelines recommend the performance of a diagnostic lumbar puncture and the administration of CNS prophylaxis for high-risk patients \[[@CR17], [@CR18]\]. Standard strategy for the prophylaxis includes systemic chemotherapy that crosses hematoencephalic barrier, intrathecal (IT) chemotherapy, radiation therapy, or their combination \[[@CR19]\]. IT chemotherapy has become the approach most frequently used because acting directly in the cerebrospinal fluid (CSF) and maintaining therapeutic drug concentrations \[[@CR20], [@CR21]\]. Main IT regimens include methotrexate (MTX) or cytarabine. Liposomal cytarabine, a sustained-release preparation of cytarabine for IT administration, allows maintaining elevated drug levels in the CSF for an extended period of time (\>14 days) \[[@CR19], [@CR22]\]. The efficacy and safety of liposomal cytarabine have been demonstrated in Burkitt's lymphoma, acute lymphoblastic leukemia, and unclassifiable highly aggressive B-cell lymphoma \[[@CR23], [@CR24]\]. However, data in patients with DLBCL in prophylactic therapy are still insufficient.

The objective of the present study was to evaluate the effectiveness and safety of the CNS prophylaxis with IT liposomal cytarabine in high-risk patients with DLBCL who were included in a prospective trial of first line systemic therapy with 6 cycles of dose-dense R-CHOP every 14 days.

Patient and methods {#Sec2}
===================

Study population {#Sec3}
----------------

A single arm open label multicentre study conducted between 2006 and 2011 evaluated dose-dense R-CHOP every 14 days in DLBCL patients (EudraCT identifier 2005-005110-20). The criteria for inclusion were as follows: aged over 18, diagnosis of DLBCL \[[@CR25]\], Eastern Cooperative Oncology Group performance status (ECOG PS) 0--2, any International Prognostic Index (IPI) if aged over 65, or IPI 0--2 (if under 65), B-cells positive for CD20, and the informed consent signed. Among the exclusion criteria were pregnancy or breastfeeding, central nervous system lymphoma, severe impairment of the renal function, human immunodeficiency virus (HIV) infection, previous treatment for DLBCL, heart failure (ejection fraction \<40 %), severe psychiatric disorders, and hypersensitivity to murine proteins or any other component of the drug. The present study included a subset of patients who required CNS prophylaxis with liposomal cytarabine (DepoCyt®) by presenting one or more of the following risk factors for CNS involvement (considered when the trial was designed): \> 30 % bone marrow infiltration, testes infiltration, retroperitoneal mass ≥10 cm, Waldeyer ring involvement, or bulky cervical nodes involvement.

Experimental procedure {#Sec4}
----------------------

R-CHOP was administered every 14 days for 6 cycles (R-CHOP14): 375 mg/m^2^ rituximab iv on day 1 plus CHOP chemotherapy regimen (750 mg/m^2^ cyclophosphamide iv + 50 mg/m^2^ adriamycin iv + 1.4 mg/m^2^ vincristine iv (maximal dose 2 mg), all on day 1 plus 100 mg oral prednisone on days 1--5). At day 2 of each cycle, 6 mg pegfilgrastim was administered subcutaneously. The tumor response, i.e., complete remission (CR), partial remission (PR), stable disease (SD), and progression disease (PD), was evaluated according to standardized response criteria for non-Hodgkin's lymphoma \[[@CR26]\]. Clinical response was evaluated after the 2nd cycle of treatment. In case of achieving CR or PR, the patient continued with four additional cycles, and the response was evaluated within 60 days after finishing the 6th cycle. Clinical follow-up was performed every 3 months, in the first and second year, and every 6 months in the following years. Criteria for withdrawal of the study included no response or PD after the 2nd cycle, partial remission after the 6th cycle, recurrence of the lymphoma, unacceptable toxicity, or refusal to continue with the treatment (Fig. [1](#Fig1){ref-type="fig"}). Liposomal cytarabine (50 mg) was administered by lumbar puncture on day 1 of the 1st, 2nd, and 6th cycle of R-CHOP14. Patients also received the concurrent administration of 4 mg dexamethasone (intrathecal or oral). CNS involvement was assessed by using standard CSF cytology or flow cytometry. Procedures were performed in accordance with the guidelines established in the Declaration of Helsinki. Toxicity due to IT liposomal cytarabine was determined according to Common Terminology Criteria for Adverse Events (AEs), version 3.0. Secondary endpoints included the evaluation of the overall survival (OS), time to progression or relapse, and progression-free survival (PFS). The analysis was performed using the intended-to-treat population. Survival functions were estimated by using Kaplan--Meier method (95 % confidence interval, 95 % CI). All the statistical procedures were performed using SAS 9.0.Fig. 1Scheme of R-CHOP cycles and evaluation times during the study

Results {#Sec5}
=======

Characteristics of high-risk patients for CNS involvement {#Sec6}
---------------------------------------------------------

From 129 patients of the multicenter study, 24 (18.6 %) cases presented at least one of the risk factors for CNS involvement considered when the trial was designed. Demographic, clinical characteristics, and risk factors for CNS involvement of this subset of patients at diagnosis are shown in Table [1](#Tab1){ref-type="table"}. Median time from diagnosis to IT prophylaxis was 0.5 months (IQR, 48.0--72.5).Table 1Demographic and clinical characteristics of the 24 patients with risk factors for CNS involvement at diagnosisNumberPercentageMedian age (limits)66.518--80Sex male1666.7ECOG 01354.2 1937.5 228.3IPI 1--21770.8 3--4729.2B symptoms520.8Ann Arbor stage I--II1145.8 III--IV1354.2Bulky disease729.2Elevated LDH1145.8Extranodal involvement1666.7 ≥2 sites416.7Risk factors for CNS prophylaxis Testes involvement28.3 Infiltration of bone marrow (\>30 %)28.3 Waldeyer ring involvement625.0 Retroperitoneal mass ≥10 cm729.1 Bulky cervical nodes involvement833.3Hollender criteria for risk of CNS involvement (albumin levels not available) 0416.7 11041.7 2520.8 3417.7 414.2Schmitz/Savage criteria for risk of CNS involvement 1 factor833.3 2--3 factors1250.0 4--6 factors416.7Other risk factors for CNS involvement Elevated LDH and ≥2 extranodal involvement28.3 Elevated LDH and Ann Arbor stage III--IV729.0 Kidney/adrenal gland involvement28.3 Breast involvement00.0*CNS* central nervous system, *ECOG* Eastern Cooperative Oncology Group performance status, *IPI* International Prognostic Index, *LDH* lactate dehydrogenase

Clinical outcomes among the 24 patients with high risk for CNS involvement {#Sec7}
--------------------------------------------------------------------------

From the 24 patients, 21 were evaluable for response 60 day after the 6th R-CHOP, 18 patients (75 %) achieved CR and 1 (4 %) PR. With a median follow-up of 40.1 months, 3 year OS was 80.8 % (95 % CI, 63.8--97.8), and 3 year PFS was 70.7 % (95 % CI 50.9--90.5) (Fig. [2](#Fig2){ref-type="fig"}). One patient (4.2 %) relapsed, and three (12.5 %) patients progressed. None of the patients experienced CNS relapse during the follow-up period. The patient who relapsed developed a mediastinal mass. Six patients (25.0 %) died during the follow-up due to lung cancer (*n* = 1), pneumonia (*n* = 1), disease progression (*n* = 2), sepsis by *Escherichia coli* (*n* = 1), and unknown cause (*n* = 1).Fig. 2Analysis of the overall survival, time to progression/relapse, and progression-free survival achieved by R-CHOP treatment

Prophylactic effect of intrathecal liposomal cytarabine {#Sec8}
-------------------------------------------------------

The analysis of the CSF was performed by cytology in 52 samples and by flow cytometry in 7 samples. CSF was negative for lymphoma infiltration at diagnosis in all patients. Adverse events of liposomal cytarabine intrathecal therapy among 70 IT infusions are shown in Table [2](#Tab2){ref-type="table"}. A total of 18 patients (75.0 %) completed the three doses of IT liposomal cytarabine. Causes of discontinuation were as follows: toxicity (*n* = 1), systemic progression (*n* = 1), medical decision (*n* = 1), change to methylprednisolone treatment (*n* = 1), or death (2). Most of IT infusions 64/70 (91.4 %) were with concurrent administration of dexamethasone.Table 2Adverse events of 70 liposomal cytarabine IT infusions for CNS prophylaxisGrade 1--2Grade 3--4Headache21Dizziness1Confusion1Nausea/vomiting1

Discussion {#Sec9}
==========

The implication of the CNS is an uncommon complication with very poor prognosis occurring in patients with DLBCL \[[@CR7]\]. While the addition of rituximab to CHOP regimen has demonstrated to improve clinical outcomes in patients with DLBCL, its effect on CNS dissemination is unclear \[[@CR27]\]. CNS prophylaxis has become a standard procedure recommended in high-risk patients since the demonstration of reducing CNS relapse and improving survival rates \[[@CR15], [@CR16]\]. The identification of risk factors at diagnosis for CNS relapse in DLBCL patients is a controversial issue. Hollender et al. described five risk factors in the pre-rituximab era: older than 60 years, elevated LDH, low albumin levels, two or more extranodal involvement, and bulky retroperitoneal mass \[[@CR28]\]. In recent years, Schmitz et al., basing on data from the MiNT trial, have found that the optimal risk model included the combination of the involvement of more than one extranodal site and elevated levels of LDH \[[@CR29]\]. When the analysis was restricted to patients receiving rituximab with chemotherapy, the risk model included advanced stage and elevated LDH. Savage et al. have recently confirmed the prognostic model proposed by the German group, which includes the five risk factors of IPI in addition to kidney/adrenal gland involvement \[[@CR30], [@CR31]\], in a large cohort of DLBCL patients. Furthermore, certain extranodal sites such as testis \[[@CR32]\], breast \[[@CR33]\], and kidney \[[@CR34]\] have also been considered to increase the risk of CNS progression \[[@CR35]--[@CR37]\]. In our study, we analyzed retrospectively the risk factors identified in the rituximab era as shown in Table [1](#Tab1){ref-type="table"}. Almost one third of the patients had simultaneously advanced stage and elevated LDH. At the time that our trial was designed, patients with known factors for a higher risk of CNS progression were included for CNS prophylaxis.

There are different strategies to prevent CNS lymphoma involvement in high-risk patients. One of them consists on high dose iv methotrexate (3.0--3.5 g/m^2^) alternating with chemotherapy \[[@CR38]--[@CR40]\]. This is an effective option; however, it can be only used in young patients due to its higher toxicity, and it also may cause the delay of the systemic therapy. The use of IT injections of antineoplastic drugs is another option for CNS involvement prophylaxis. Among the different IT prophylactic strategies, liposomal cytarabine allows maintaining cytotoxic levels of the free drug in the CSF for an extended period of time (\>14 days) \[[@CR19], [@CR22]\]. The administration of IT liposomal cytarabine is less frequent than conventional therapies, leading to minimize the patient's discomfort and risks associated with lumbar puncture procedures. Randomized clinical trials have demonstrated similar efficacy of IT liposomal cytarabine as IT MTX or conventional cytarabine in patients with leptomeningeal infiltration \[[@CR23], [@CR41], [@CR42]\]. Furthermore, in comparison with IT cytarabine, liposomal cytarabine has demonstrated higher response rates and a significant improvement in quality of life \[[@CR43]\]. The efficacy of liposomal cytarabine has been demonstrated in Burkitt's lymphoma, acute lymphoblastic leukemia, and unclassifiable highly aggressive B-cell lymphoma \[[@CR23], [@CR24]\]. However, there are no data on patients with DLBCL for prophylactic purposes. Although only 24 patients were treated in our study with prophylactic IT liposomal cytarabine, none of them developed CNS relapse during a follow-up period of 40.1 months.

Our scheme of liposomal cytarabine administration (at 1st, 2nd, and 6th cycle of R-CHOP14) was designed to reduce half of the injections of the standard IT therapies, and taking into account that the risk of CNS involvement is higher during the first cycles, when the tumor is more active, leaving the last dose as consolidation. It has been demonstrated in this trial that the scheme is well tolerated and safe. Clinical studies evaluating safety of IT liposomal cytarabine in patients with DLBCL are insufficient. Most of the safety data of IT liposomal cytarabine have been reported in highly pre-treated patients with CNS involvement and with other aggressive lymphoproliferative diseases, such as Burkitt lymphoma and lymphoblastic leukemia. Commonly described AEs associated with liposomal cytarabine include headache, nausea, fever, vomiting, and back pain. Reported grade 3--4 AEs include arachnoiditis, persistent lumbar pain, peripheral sensory neuropathy, motor neuropathy, and optical nerve neuritis \[[@CR44]--[@CR47]\]. On the other hand, one study has reported severe neurotoxicity (including seizures, encephalitis, cauda equina syndrome, or pseudotumor cerebri) associated with IT liposomal cytarabine administered concurrently with high-dose MTX and cytarabine in patients with acute lymphocytic leukemia \[[@CR48]\]. Therefore, the concurrent administration of these drugs is contraindicated. Patients in our study were receiving their first line systemic therapy and prophylactic IT liposomal cytarabine, and toxicity has been much lower, 25 % of patients suffered IT chemotherapy related events, and only 8.3 % suffered grade 3/4 AEs. Patients experienced grade 1--2 headache (*n* = 2), dizziness (*n* = 1), confusion (*n* = 1), and grade 3--4 headache (*n* = 1) and nausea/vomiting (*n* = 1). In a previous study of our group, Garcia-Marco et al. evaluated retrospectively the efficacy and safety of the therapeutic use of liposomal cytarabine for the treatment of lymphomatous meningitis in patients with lymphoma, mainly DLBCL \[[@CR49]\]. Fifty patients received corticosteroids for the prevention of chemical arachnoiditis. The most commonly used agent was dexamethasone (usually 4 mg po twice daily for 5 days with each cycle of liposomal cytarabine). Liposomal cytarabine was well tolerated and produced no AEs in 30 out of 54 of the patients. In the remaining ones, headache grade 1--2 (*n* = 17) was the most common AE reported, followed of nausea (*n* = 7), fever (*n* = 7), vomiting (*n* = 6), neurologic deficits (*n* = 2), and dizziness (*n* = 1). By contrast with our study, one patient (receiving also dexamethasone) did have neurotoxicity. Recently, Krawczyk et al. also determined efficacy and safety of liposomal cytarabine as CNS prophylaxis in patients with DLBCL \[[@CR50]\]. All patients received oral prednisone (as an element of the R-CHOP regimen) on administration of intrathecal liposomal cytarabine. In their study, 59 out of 79 patients (74.7 %) experienced AEs, mainly headache. Other AEs were nausea (*n* = 13), fever (*n* = 10), vomiting (*n* = 5), dizziness (*n* = 3), neurological deficits (*n* = 3), and myelopathy (*n* = 1). The rate of AEs was higher than in our study, as seven patients suffered grade 3--4. In another study of our group, 54 patients with lymphoma (25 DLBCL) received prophylactic IT cytarabine with 4 mg IT dexamethasone and 20 mg iv dexamethasone on day 1, and only 4 (3.5 %) grade 3 AEs among 112 administrations were observed. Therefore, it seems that the concurrent administration of dexamethasone can avoid the development of chemical arachnoiditis \[[@CR51]\]. The main limitation of the present study was the low number of high-risk patients available in the original trial. Nevertheless, it is important to highlight that our results are derived from a prospective study defined by a homogeneous systemic treatment in all the patients.

In conclusion, IT liposomal cytarabine has demonstrated being safe, feasible, and effective for CNS prophylaxis, causing few associated risks and little discomfort to patients with DLBCL.
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